Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4

BBA Advances

Mikihiko Naito¹  Keigo Sano²  Fukuko Kishi²  Miki Irie²  Rie Kawamoto²  Susumu Itoh²  Etsu Tashiro²  Waka Nagano²  Haruka Ishikawa²  Naoko Nakano²  Mariko Ikuta²  Takahisa Nakane³ 

[1] Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan;Laboratory of Biochemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan;Laboratory of Natural Products Chemistry, Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan;

关键词: Anticancer drug;    Malignant mesothelioma;    Narciclasine;    TEAD;    YAP;   

DOI  :  

来源: DOAJ

【 摘 要 】

Yes-associated protein (YAP) is involved in development, cell growth, cell size, and homeostasis and plays a key role in the progression of various cancers. Among them, constitutive activation of YAP can often be observed in malignant mesothelioma, which arises in the pleura, peritoneum, and pericardium because of inactivation of the Hippo pathway. To date, however, only less-effective treatments such as chemotherapy, radiation therapy, and surgery are available for patients with malignant mesothelioma.In this study, we identified narciclasine as a novel YAP inhibitor that prevents YAP from interacting with TEAD4 because it competes with TEAD4 for binding to YAP. Furthermore, narciclasine could perturb the cell growth and colony formation of malignant mesothelioma NCI-H290 cells in addition to inhibiting their growth in nude mice. Therefore, narciclasine might be a potential seed for a novel antitumor drug against malignant mesothelioma and other cancers in which hyperactivation and/or overexpression of YAP are observed.

【 授权许可】

Unknown